---
audienceLevel: patient
cancerTypes:
- breast
citation: NCI, 2025
language: en
lastReviewed: '2025-12-30'
license: public_domain
reviewFrequency: quarterly
source: NCI
sourceType: 02_nci_core
status: active
tags:
- treatment
title: Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf - NCI
url: https://www.cancer.gov/about-cancer/treatment/drugs/pertuzumabtrastuzumabandhyaluronidase-zzxf
version: v1
---

# Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf - NCI

# Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf

Placeholder slot

(per-TOO-zoo-mab tras-TOO-zoo-mab â€¦ HY-al-yoo-RAH-nih-days)

This targeted therapy combination consists of two monoclonal antibodies, pertuzumab and trastuzumab, and hyaluronidase-zzxf, a recombinant form of a naturally occurring enzyme. Pertuzumab and trastuzumab bind to different parts of the HER2 protein on the surface of some cancer cells, causing the cells to stop growing and die. Both also trigger a type of immune reaction that kills cells that have a lot of HER2. Hyaluronidase-zzxf makes it easier for the body to absorb these targeted therapies.

US Brand Name(s)

Phesgo

FDA Approved

Yes

[FDA label information for this drug is available at DailyMed.](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27dd5e6b-72cd-458d-a015-cf4dab5800da&audience=consumer)

## Use in Cancer

Pertuzumab, trastuzumab, and hyaluronidase-zzxf
is approved to be given with [docetaxel](/Common/PopUps/popDefinition.aspx?id=45382&version=Patient&language=English) or other chemotherapy to treat:

- **[Breast cancer](/Common/PopUps/popDefinition.aspx?id=444971&version=Patient&language=English)** that is [HER2 positive](/Common/PopUps/popDefinition.aspx?id=737998&version=Patient&language=English). It is used:
- with chemotherapy as [neoadjuvant therapy](/Common/PopUps/popDefinition.aspx?id=45800&version=Patient&language=English) (to shrink the tumor before surgery) in adults with [locally advanced](/Common/PopUps/popDefinition.aspx?id=45955&version=Patient&language=English), [inflammatory](/Common/PopUps/popDefinition.aspx?id=45313&version=Patient&language=English), or [early-stage breast cancer](/Common/PopUps/popDefinition.aspx?id=446564&version=Patient&language=English)
- with chemotherapy as [adjuvant therapy](/Common/PopUps/popDefinition.aspx?id=45587&version=Patient&language=English) in adults with early-stage breast cancer who have a [high risk](/Common/PopUps/popDefinition.aspx?id=45079&version=Patient&language=English) that their cancer will [recur](/Common/PopUps/popDefinition.aspx?id=45862&version=Patient&language=English) (come back)
- with the chemotherapy drug docetaxel in adults with [metastatic](/Common/PopUps/popDefinition.aspx?id=44058&version=Patient&language=English) breast cancer that has not been treated with anti-HER2 therapy or chemotherapy

Pertuzumab, trastuzumab, and hyaluronidase-zzxf is a fixed-[dose](/Common/PopUps/popDefinition.aspx?id=44664&version=Patient&language=English) [combination](/Common/PopUps/popDefinition.aspx?id=688810&version=Patient&language=English) of [pertuzumab](/Common/PopUps/popDefinition.aspx?id=340934&version=Patient&language=English) and [trastuzumab](/Common/PopUps/popDefinition.aspx?id=45439&version=Patient&language=English) that is given as a [subcutaneous](/Common/PopUps/popDefinition.aspx?id=45914&version=Patient&language=English) [injection](/Common/PopUps/popDefinition.aspx?id=44678&version=Patient&language=English). It can be given in less time than pertuzumab or trastuzumab, which are given as [infusions](/Common/PopUps/popDefinition.aspx?id=45738&version=Patient&language=English). For more information about pertuzumab and trastuzumab that may apply to pertuzumab, trastuzumab, and hyaluronidase-zzxf, see the Drug Information Summaries for [Pertuzumab](/about-cancer/treatment/drugs/pertuzumab) and [Trastuzumab](/about-cancer/treatment/drugs/trastuzumab).

## More About Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf

[Definition from the NCI Drug Dictionary](https://www.cancer.gov/publications/dictionaries/cancer-drug/def/801876) - Detailed scientific definition and other names for this drug.

MedlinePlus Information on [Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf](https://medlineplus.gov/druginfo/meds/a620048.html) - A lay language summary of important information about this drug that may include the following:

- warnings about this drug,
- what this drug is used for and how it is used,
- what you should tell your doctor before using this drug,
- what you should know about this drug before using it,
- other drugs that may interact with this drug, and
- possible side effects.

Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.

## Research Results and Related Resources

[Targeted Therapy to Treat Cancer](https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies)

[Monoclonal Antibodies](https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/monoclonal-antibodies)

## Clinical Trials Accepting Patients

[Find Clinical Trials for Pertuzumab, Trastuzumab, And Hyaluronidase-zzxf](https://www.cancer.gov/research/participate/clinical-trials/intervention/C173339) - Check for trials from NCI's list of cancer clinical trials now accepting patients.
